Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011
Mon, May 2, 2011
Fri, April 29, 2011
Thu, April 28, 2011
Wed, April 27, 2011
Tue, April 26, 2011
Mon, April 25, 2011
Fri, April 22, 2011
Thu, April 21, 2011
Wed, April 20, 2011
Tue, April 19, 2011
Mon, April 18, 2011
Sun, April 17, 2011
Fri, April 15, 2011
Thu, April 14, 2011
Wed, April 13, 2011

AVEO Pharmaceuticals, Inc. to Present at the Deutsche Bank Securities 36th Annual Health Care Conference


//health-fitness.news-articles.net/content/2011/ .. curities-36th-annual-health-care-conference.html
Published in Health and Fitness on Tuesday, April 26th 2011 at 3:40 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Deutsche Bank Securities 36th Annual Health Care Conference on Tuesday, May 3, 2011 at 2:50 p.m. (EDT) at the InterContinental Hotel in Boston.

A live webcast of AVEO's presentation can be accessed by visiting the investors section of the companya™s website at investor.aveopharma.com. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsa™ lives. The companya™s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEOa™s second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEOa™s proprietary Human Response Platforma" is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the companya™s website at www.aveopharma.com.


Publication Contributing Sources